1
|
Durán Botía F, Fernández-Aceñero MJ, Ruiz Adelantado I, de Miguel P, Molino Á, Ortega Medina L. Bone metastasis of papillary thyroid carcinoma simulating a pulmonary origin. Unusual immunohistochemistry leading to misdiagnosis. Rev Esp Patol 2020; 53:264-267. [PMID: 33012498 DOI: 10.1016/j.patol.2019.08.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/25/2019] [Revised: 08/06/2019] [Accepted: 08/15/2019] [Indexed: 06/11/2023]
Abstract
Immunophenotypical features from tumors can be variable and, sometimes, confusing. We herein report a 61 year old woman with two foci of papillary thyroid microcarcinoma who developed a bone lesion four months after total thyroidectomy/central lymphadenectomy (mpT1aN0), with an immunohistochemical pattern suggestive of a pulmonary rather than a thyroid origin (CK7, napsin-A and TTF1 positive; and negative thyroglobulin). Further biomarkers (HBME-1 and PAX8) were performed in order to confirm primary tumor, leading to conclusion of a bone metastasis from thyroid papillary carcinoma. We believe it is always advisable to perform more than one biomarker as part of a panel to get a more reliable diagnosis.
Collapse
Affiliation(s)
- Fernando Durán Botía
- Department of Pathology, Hospital Universitario Clínico San Carlos, Calle del Profesor Martín Lagos s/n, 28040 Madrid, Spain.
| | - María Jesús Fernández-Aceñero
- Department of Pathology, Hospital Universitario Clínico San Carlos, Calle del Profesor Martín Lagos s/n, 28040 Madrid, Spain
| | - Irene Ruiz Adelantado
- Department of Pathology, Hospital Universitario Clínico San Carlos, Calle del Profesor Martín Lagos s/n, 28040 Madrid, Spain
| | - Paz de Miguel
- Department of Endocrinology, Hospital Universitario Clínico San Carlos, Spain
| | - Ángel Molino
- Department of Internal Medicine, Hospital Universitario Clínico San Carlos, Spain
| | - Luis Ortega Medina
- Department of Pathology, Hospital Universitario Clínico San Carlos, Calle del Profesor Martín Lagos s/n, 28040 Madrid, Spain
| |
Collapse
|
2
|
Ayan AK, Erdemci B, Orsal E, Bayraktutan Z, Akpinar E, Topcu A, Turkeli M, Seven B. Is there any correlation between levels of serum ostepontin, CEA, and FDG uptake in lung cancer patients with bone metastasis? Rev Esp Med Nucl Imagen Mol 2015; 35:102-6. [PMID: 26521996 DOI: 10.1016/j.remn.2015.09.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Revised: 09/04/2015] [Accepted: 09/07/2015] [Indexed: 11/25/2022]
Abstract
OBJECTIVE In this study, an evaluation was made of the relationship between the serum levels of carcinoembryonic antigen (CEA), osteopontin (OPN), and the semi-quantitative parameters of 18-fluoro-2-deoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in lung cancer patients with bone metastasis. MATERIAL AND METHODS The evaluation included 42 non-small cell lung cancer (NSCLC) and 31 small cell lung cancer (SCLC) patients who were referred to our institution for staging by (18)F-FDG PET/CT. The biochemical parameters measured included CEA and OPN serum levels. RESULTS Serum levels of OPN in NSCLC patients with and without bone metastasis were 21.20±4.97 ng/ml and 13.33±4.53 ng/ml, respectively (p<0.05). In SCLC patients with and without bone metastasis serum OPN levels were 23.95±4.78 ng/ml and 17.30±3.09 ng/ml, respectively (p<0.05). Serum levels of CEA in NSCLC patients with and without bone metastasis were 33.79±6.49 ng/ml and 11.74±2.96 ng/ml, respectively (p<0.05). In SCLC patients with and without bone metastasis serum levels of CEA were 28.93±4.59 ng/ml and 13.88±4.47 ng/ml, respectively (p<0.05). There were no correlations between primary tumor SUVmax, and serum levels of CEA and OPN. CONCLUSIONS Bone metastasis can be detected in patients with lung cancer by measuring CEA and OPN levels. Increased levels of CEA and OPN levels may be considered an early warning sign in patients needing accurate imaging, as they are at higher risk of bone metastasis.
Collapse
Affiliation(s)
- A K Ayan
- Department of Nuclear Medicine, Ataturk University Faculty of Medicine, Erzurum, Turkey.
| | - B Erdemci
- Department of Radiation Oncology, Ataturk University Faculty of Medicine, Erzurum, Turkey
| | - E Orsal
- Department of Nuclear Medicine, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey
| | - Z Bayraktutan
- Department of Biochemistry, Erzurum Regional Training and Research Hospital, Erzurum, Turkey
| | - E Akpinar
- Department of Pharmacology, Ataturk University Faculty of Medicine, Erzurum, Turkey
| | - A Topcu
- Department of Pharmacology, Recep Tayyip Erdogan University Faculty of Medicine, Rize, Turkey
| | - M Turkeli
- Department of Internal Medicine, Ataturk University Faculty of Medicine, Erzurum, Turkey
| | - B Seven
- Department of Nuclear Medicine, Mevlana University Faculty of Medicine, Konya, Turkey
| |
Collapse
|
3
|
Caglar M, Kupik O, Karabulut E, Høilund-Carlsen PF. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan? Rev Esp Med Nucl Imagen Mol 2015; 35:3-11. [PMID: 26514321 DOI: 10.1016/j.remn.2015.08.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2015] [Revised: 08/17/2015] [Accepted: 08/30/2015] [Indexed: 11/18/2022]
Abstract
AIM To examine the value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for the detection of bone metastasis in breast cancer patients and assess whether whole body bone scan (BS) with (99m)Tc-methylene diphosphonate provides any additional information. MATERIAL AND METHODS Study group comprised 150 patients, mean age 52 years (range 27-85) with breast cancer, suspected of having bone metastases. All patients had undergone both FDG-PET/CT and BS with or without single photon emission tomography/computed tomography (SPECT/CT) within a period of 6 weeks. The final diagnosis of bone metastasis was established by histopathological findings, additional imaging, or clinical follow-up longer than 10 months. Cancer antigen 15-3 (CA15-3) and carcinoembryogenic antigen (CEA) were measured in all patients. RESULTS Histologically 83%, 7% and 10% had infiltrating ductal, lobular and mixed carcinoma respectively. Confirmed bone metastases were present in 86 patients (57.3%) and absent in 64 (42.7%). Mean CA15-3 and CEA values in patients with bone metastases were 74.6ng/mL and 60.4U/mL respectively, compared to 21.3ng/mL and 3.2U/mL without metastases (p<0.001). The sensitivity of FDG-PET/CT for the detection of bone metastases was 97.6% compared to 89.5% with SPECT/CT. In 57 patients, FDG-PET/CT correctly identified additional pulmonary, hepatic, nodal and other soft tissue metastases, not detected by BS. CONCLUSION Our findings suggest that FDG-PET/CT is superior to BS with or without SPECT/CT.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor/blood
- Bone Neoplasms/blood
- Bone Neoplasms/diagnostic imaging
- Bone Neoplasms/secondary
- Breast Neoplasms/pathology
- Carcinoembryonic Antigen/blood
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/diagnostic imaging
- Carcinoma, Ductal, Breast/secondary
- Carcinoma, Lobular/blood
- Carcinoma, Lobular/diagnostic imaging
- Carcinoma, Lobular/secondary
- Female
- Fluorine Radioisotopes/analysis
- Fluorodeoxyglucose F18/analysis
- Humans
- Middle Aged
- Mucin-1/blood
- Positron Emission Tomography Computed Tomography
- Positron-Emission Tomography
- Radiopharmaceuticals/analysis
- Retrospective Studies
- Single Photon Emission Computed Tomography Computed Tomography
- Technetium Tc 99m Medronate/analysis
- Whole Body Imaging
Collapse
Affiliation(s)
- M Caglar
- Hacettepe University Medical Faculty, Department of Nuclear Medicine, Sihhiye, Ankara 06100, Turkey.
| | - O Kupik
- Hacettepe University Medical Faculty, Department of Nuclear Medicine, Sihhiye, Ankara 06100, Turkey
| | - E Karabulut
- Hacettepe University Medical Faculty, Department of Biostatistics, Sihhiye, Ankara 06100, Turkey
| | - P F Høilund-Carlsen
- Department of Nuclear Medicine, Odense University Hospital, 5000 Odense C, Denmark
| |
Collapse
|
4
|
Borsò E, Boni G, Mazzarri S, Cocciaro A, Gambacciani C, Traino AC, Manca G, Grosso M, Scatena C, Ortenzi V, Vannozzi R, Marzola MC, Rubello D, Mariani G. Disseminated bone metastases from occult thyroid cancer effectively treated with debulking surgery and a single dosimetry-guided administration of radioiodine. Rev Esp Med Nucl Imagen Mol 2015; 34:111-5. [PMID: 25455505 DOI: 10.1016/j.remn.2014.09.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2014] [Revised: 09/29/2014] [Accepted: 09/30/2014] [Indexed: 11/21/2022]
Abstract
In this paper we report on a successful management of multiple bone metastases from differentiated thyroid cancer. In 2007, a 75-year-old female patient, previously referred for thyroidectomy for multinodular goiter, underwent surgical removal of a lumbar mass with histological findings of metastasis from well differentiated thyroid cancer. After surgery, serum thyroglobulin (sTg) was 204.4 ng/mL. A diagnostic/dosimetric (123)I WBS was performed, following stimulation by rTSH. Serial WBSs were acquired, along with SPECT/CT and bone scan for localization of lesions. sTg raised to 3.810 ng/mL, and (123)I WBS showed thyroid remnants and numerous areas with high iodine-uptake corresponding to skeletal sites, the two largest loading on the skull, with osteolytic pattern. Calculated radiation absorbed dose for skull lesions, determined by mean of MIRD methodology, was 63.5 mGy/MBq. The patient underwent surgical removal of the two major skull lesions. Successively, 100 mCi (131)I was administered after stimulation by rTSH, with stimulated sTg 297 ng/mL. After 8 months, diagnostic WBS was negative both for remnants and metastases and rTSH-stimulated Tg was 0.6 ng/mL. To date, the patient has maintained sTg values <1 ng/mL during L-T4 suppressive therapy and after rTSH stimulations. In this unusual case of extensive bone cancerous involvement with high iodine avidity, a multidisciplinary approach based on surgery and dosimetry-guided radiometabolic therapy allowed to accurately assess the patient, execute a small number of treatments and achieve a complete remission of the disease in a very short time, with no additive morbidity.
Collapse
|
5
|
Miñana B, Cózar JM, Alcaraz A, Morote J, Gómez-Veiga FJ, Solsona E, Rodríguez-Antolín A, Carballido J. Bone health in patients with prostate cancer. Actas Urol Esp 2014; 38:685-93. [PMID: 24934457 DOI: 10.1016/j.acuro.2014.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2014] [Revised: 05/01/2014] [Accepted: 05/05/2014] [Indexed: 11/26/2022]
Abstract
CONTEXT In patients with prostate cancer, bone health is compromised by advanced age at diagnosis, androgen suppression treatments and the developmentofbone metastases. In this paper the medical literature is reviewed in order to update the state of the art on their incidence, prevention and management. EVIDENCE ACQUISITION A literature review about bone involvement in patients with prostate cancer in different clinical settings is performed. SYNTHESIS OF THE EVIDENCE Decreased bone mineral density is higher in patients diagnosed of prostate cancer before starting treatment than in healthy men with the same age. During the first year of treatment, a severe loss bone density is reported due to androgen suppression therapy. From then on, loss bone density seems to slow down, persisting at long-term. It is important to know the starting point and the dynamics of loss bone in order to prevent its progression. The skeletal events have an important impact on quality of life in patients with prostate cancer. Both Denosumab and Zoledronic Acid have proven effective in reducing loss bone. CONCLUSIONS The prevention and management of bone involvement in patients with prostate cancer is critical to quality of life in these patients and requires an individualized approach. Before starting a prolonged androgen deprivation, baseline risk of fracture should be evaluated in order to adopt the proper protective measures. In patients with metastases, early treatments reducing the risk of bone events should be taken into account.
Collapse
Affiliation(s)
- B Miñana
- Servicio de Urología, Hospital Morales Meseguer, Universidad Católica San Antonio, UCAM, Murcia, España.
| | - J M Cózar
- Servicio de Urología, Hospital Virgen de las Nieves, Granada, España
| | - A Alcaraz
- Servicio de Urología, Hospital Clínic, Barcelona, España
| | - J Morote
- Servicio de Urología, Hospital Vall de Hebrón, Barcelona, España
| | | | - E Solsona
- Servicio de Urología, IVO, Valencia, España
| | | | - J Carballido
- Servicio de Urología, Hospital Puerta de Hierro, Madrid, España
| |
Collapse
|
6
|
Ozdemir E, Poyraz NY, Keskin M, Kandemir Z, Turkolmez S. (18)F-FDG PET/CT findings in a case with HIV (-) Kaposi sarcoma. Rev Esp Med Nucl Imagen Mol 2013; 33:175-7. [PMID: 24119549 DOI: 10.1016/j.remn.2013.08.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2013] [Revised: 08/28/2013] [Accepted: 08/29/2013] [Indexed: 11/30/2022]
Abstract
Although mucocutaneous sites are the most frequently encountered sites of involvement, Kaposi Sarcoma (KS) may also occasionally involve the breast and the skeletal, endocrine, urinary and nervous systems.. Various imaging modalities may be used to delineate the extent of the disease by detecting unexpected sites of involvement. Herein, we report a case of classical type KS, in whom staging with (18)F-FDG PET/CT imaging disclosed widespread disease and unexpected findings of bone and salivary gland involvement.
Collapse
Affiliation(s)
- E Ozdemir
- Department of Nuclear Medicine, Ataturk Training and Research Hospital, Ankara, Turkey.
| | - N Y Poyraz
- Department of Nuclear Medicine, Ataturk Training and Research Hospital, Ankara, Turkey
| | - M Keskin
- Department of Nuclear Medicine, Ataturk Training and Research Hospital, Ankara, Turkey
| | - Z Kandemir
- Department of Nuclear Medicine, Ataturk Training and Research Hospital, Ankara, Turkey
| | - S Turkolmez
- Department of Nuclear Medicine, Ataturk Training and Research Hospital, Ankara, Turkey
| |
Collapse
|
7
|
Sanromán-Álvarez P, Simal-Julián JA, Miranda-Lloret P, Pérez-Borredá P, Botella-Asunción C. [Sacral metastasis simulating aneurysmal bone cyst]. Neurocirugia (Astur) 2013; 25:77-80. [PMID: 23731559 DOI: 10.1016/j.neucir.2013.03.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2013] [Revised: 03/22/2013] [Accepted: 03/25/2013] [Indexed: 10/26/2022]
Abstract
Cystic spinal lesions with characteristic patterns, such as the presence of haematic fluid-fluid levels (H-FFL), have been associated with many tumoral lineages, more frequently with aneurysmal bone cyst (ABC) and exceptionally with metastasis. We present the case of a 60-year-old man with the finding of a sacral cystic bone lesion with H-FFL, with initial suspicion of ABC and confirmed diagnosis of metastasis. The case presented is, to our knowledge, the second case published of spinal cystic bone metastasis with H-FFL pattern with unknown primary tumour at the time of diagnosis and the only one that received resective surgical treatment, achieving pulmonary and metastatic disease control with good quality of life after 1 year of follow up.
Collapse
Affiliation(s)
- Pablo Sanromán-Álvarez
- Departamento de Neurocirugía, Hospital Universitario y Politécnico La Fe, Valencia, España.
| | | | - Pablo Miranda-Lloret
- Departamento de Neurocirugía, Hospital Universitario y Politécnico La Fe, Valencia, España
| | - Pedro Pérez-Borredá
- Departamento de Neurocirugía, Hospital Universitario y Politécnico La Fe, Valencia, España
| | | |
Collapse
|